Lucy Godley to Myeloproliferative Disorders
This is a "connection" page, showing publications Lucy Godley has written about Myeloproliferative Disorders.
Connection Strength
3.949
-
Germ line risk variants: beyond cancer. Blood. 2023 08 17; 142(7):616-617.
Score: 0.838
-
DDX41-associated susceptibility to myeloid neoplasms. Blood. 2023 03 30; 141(13):1544-1552.
Score: 0.816
-
Inherited predisposition to myeloid malignancies. Blood Adv. 2019 09 10; 3(17):2688.
Score: 0.638
-
A new family with a germline ANKRD26 mutation and predisposition to myeloid malignancies. Leuk Lymphoma. 2014 Dec; 55(12):2945-6.
Score: 0.439
-
Germ line DDX41 mutations define a unique subtype of myeloid neoplasms. Blood. 2023 02 02; 141(5):534-549.
Score: 0.202
-
Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022 11 24; 140(21):2228-2247.
Score: 0.199
-
Classification of rare pediatric myeloid neoplasia-Quo vadis? Leukemia. 2022 12; 36(12):2947-2948.
Score: 0.198
-
Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia. Leukemia. 2022 12; 36(12):2827-2834.
Score: 0.198
-
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 09 15; 140(11):1200-1228.
Score: 0.197
-
Recognition of familial myeloid neoplasia in adults. Semin Hematol. 2017 04; 54(2):60-68.
Score: 0.135
-
Gene mutations, epigenetic dysregulation, and personalized therapy in myeloid neoplasia: are we there yet? Semin Oncol. 2011 Apr; 38(2):196-214.
Score: 0.089